Please login to the form below

Not currently logged in
Email:
Password:

Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

J&J earnings top expectations, but feels the squeeze in US

J&J earnings top expectations, but feels the squeeze in US

Nevertheless, the company's annual revenues rose almost 7% to $81.6bn, driven up by three rising star performers in particular: psoriasis treatment Stelara, leukaemia drug Imbruvica and multiple myeloma Darzalex.

Latest news

  • J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

    Novartis’ Cosentyx can put some of its fast growth in psoriasis down to data showing it was more effective than Johnson &Johnson’s widely-used Stelara, but a new trial has ... In a head-to-head challenge, J&J’s recently approved follow-up to

  • New data keeps AbbVie’s star pipeline therapies on track New data keeps AbbVie’s star pipeline therapies on track

    The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

  • AstraZeneca’s Lupus treatment misses mark in trial AstraZeneca’s Lupus treatment misses mark in trial

    Its blockbuster Stelara produced encouraging phase II results in the disease last November, while Gilead is working with Verily on an early stage research project to better understand the disease.

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    Tremfya (guselkumab) is a follow-up to J&J’s IL-23/IL-12 inhibitor Stelara (ustekinumab) that rakes in blockbuster revenues but is facing the threat of competition from newer ... Stelara was a $4bn product for J&J’s Janssen Pharma unit last year, but

More from news
Approximately 14 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for

  • Back to the future Back to the future

    Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics